Every 10-Q that Insight Molecular Diagnostics Inc. (IMDX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IMDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMDX filings page.
Insight Molecular Diagnostics Inc. reported continuing early-stage commercialization with very limited revenue and significant losses for the quarter ended June 30, 2026. Net revenue was $239,000 in the quarter and $271,000 for the first six months of 2026, down sharply from the prior-year period, driven by a business heavily concentrated in one life sciences customer and early GraftAssureIQ kitted product sales.
The company recorded a net loss of $11.3 million for the quarter and $15.6 million year-to-date, with operating expenses of $11.6 million in the quarter largely from research and development and commercialization activities. Operating cash outflow was $16.9 million in the first half. Liquidity was supported by a February 2026 registered direct offering that generated $24.6 million of net proceeds, including an investment from strategic partner Bio-Rad, raising cash and cash equivalents to $17.8 million plus $972,000 of restricted cash at June 30, 2026. Contingent consideration liabilities related to past acquisitions declined to $40.2 million after remeasurement, and total shareholders’ deficit narrowed from $31.5 million to $21.3 million. Management’s going-concern analysis concludes that, after planned cost controls and the recent financing, it expects to have sufficient cash for at least 12 months, though it still anticipates ongoing operating losses and negative cash flows as it develops transplant and oncology diagnostics.
Insight Molecular Diagnostics reported a sharply smaller business in early 2026 but an improved bottom line driven by non-cash items and new equity capital. For the quarter ended March 31, 2026, net revenue was just $32 thousand versus $2.1 million a year earlier, as all revenue came from laboratory services in the United States. Despite this, net loss narrowed to $4.3 million from $6.7 million, helped by a $5.9 million decrease in the fair value of Chronix-related contingent consideration.
Operating expenses fell to $4.4 million from $8.1 million, while net cash used in operating activities increased to $7.6 million. The company strengthened liquidity through a February 2026 registered direct offering that generated $26.0 million in gross proceeds and about $24.6 million in net proceeds, contributing to $28.2 million in cash and cash equivalents at quarter-end. Total assets were $40.4 million, with $51.1 million in liabilities and a shareholders’ deficit of $10.7 million. Management concluded that, despite ongoing expected losses and negative operating cash flows, existing resources are sufficient to meet projected needs for at least 12 months, so substantial doubt about continuing as a going concern has been alleviated for this period.
Insight Molecular Diagnostics (IMDX) filed its Q3 2025 10‑Q, reporting net revenue of $260K versus $115K a year ago and a net loss of $10.9M versus $13.5M. Gross profit was $139K as operating expenses reached $11.2M, including R&D of $3.9M and sales and marketing of $1.4M.
For the nine months, revenue was $2.916M versus $395K last year, with a net loss of $27.3M. Operating cash use was $16.6M. The balance sheet showed cash and cash equivalents of $18.7M, total assets of $43.9M, total liabilities of $53.1M, and a shareholders’ deficit of $9.2M.
Management evaluated going concern and concluded it will have sufficient cash for at least the next 12 months, aided by cost controls and the February 2025 offering that raised $29.1M gross (net proceeds ~$28.7M). Commercial progress included Medicare coverage and a $2,753 per‑result reimbursement for GraftAssureCore and initial RUO kit sales under the Bio‑Rad partnership. Common shares outstanding were 28,664,437 as of November 3, 2025.